Farooq Sajid, Abu Omar Mohannad, Salzman Gary A
a Pulmonary and Critical Care , University of Missouri-Kansas City , Kansas City , MO , USA.
Hosp Pract (1995). 2018 Aug;46(3):144-151. doi: 10.1080/21548331.2018.1464363. Epub 2018 Apr 23.
Acute chest syndrome (ACS) is a leading complication of sickle cell disease (SCD) with significant morbidity and mortality. ACS is the most common cause of death and the second most common cause of hospitalization in patients with SCD. Delineating the specific cause of ACS is often difficult, and multiple risk factors that precipitate ACS frequently coexist. The prominent risk factors include infection, hypoxia, bronchial hyperresponsiveness, the SCD genotype, and opioid use. The key to the successful treatment of ACS is early recognition and initiation of treatment without delay. The main goal is to prevent and treat acute respiratory failure and, thus, minimize irreversible lung damage. This review focuses on the risk factors, pathogenesis, clinical presentation, and management of ACS.
急性胸综合征(ACS)是镰状细胞病(SCD)的主要并发症,具有较高的发病率和死亡率。ACS是SCD患者最常见的死亡原因和第二常见的住院原因。确定ACS的具体病因往往很困难,引发ACS的多种危险因素常常并存。主要危险因素包括感染、缺氧、支气管高反应性、SCD基因型和阿片类药物使用。成功治疗ACS的关键是早期识别并立即开始治疗。主要目标是预防和治疗急性呼吸衰竭,从而将不可逆的肺损伤降至最低。本综述重点关注ACS的危险因素、发病机制、临床表现和管理。